Authors


Cmdr John Burke

Latest:

Florida PDMP Demonstrates Positive Results

The efficiency and value of the nation’s Prescription Drug Monitoring Programs (PDMPS) have been questioned from time to time by various groups.



Davy James, Managing Editor, Specialty Pharmacy Times

Latest:

Hy-Vee Presents Annual Caregiver Award at Armada Specialty Pharmacy Summit

A commonly held axiom in specialty pharmacy is that the patient is at the center of every action.


Michael C. Barnes

Latest:

Time to Take a Look at the Man in the Mirror

The trial of Michael Jackson's doctor will highlight the problem of prescription drug abuse, and expose systematic failures of the US health care system.



Yvette C. Terrie, BS Pharm, RPh

Latest:

Self-Care Measures Can Help Prevent and Treat Headaches

Pharmacists can make clinical recommendations tailored to patients’ individual needs.


Edmondo J. Robinson, MD, MBA

Latest:

Factors Associated With Employee Participation in a Value-Based Insurance Design Initiative

We describe enrollment in a voluntary VBID initiative. Uptake was suboptimal, suggesting that barriers to enrollment may have significant implications for the overall effectiveness of VBID.


Ammie J. Patel, PharmD, BCACP

Latest:

November Case Studies- Cough

This issue's OTC Cases answer common questions about a cough.




Rachel C. Lee, PharmD, BCPS, CPP

Latest:

Transitions of Care for Patients with Atrial Fibrillation

Atrial fibrillation, the most common cardiac arrhythmia, is strongly associated with increased morbidity and mortality and has become a major global public health challenge.


Brian Daleiden

Latest:

A Sustainable Approach to DSCSA Compliance for the Long Term

Specialty pharmacies must plan carefully to ensure compliance with new supply chain rules.


David Yoder, PharmD, MBA

Latest:

Payers' Views on the Heterogeneity of Treatment Effect in Oncology

When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.




Celeste Karpow, PharmD candidate

Latest:

Case Studies (May 2015)

What should these pharmacists do?


Brian Hoyle, PhD

Latest:

Extremely Virulent Strain of Klebsiella pneumoniae Reaches United States

An extremely virulent (hypermucoviscous) strain of Klebsiella pneumoniae (K pneumoniae) that is resistant to carbapenem and colistin has been isolated for the first time from a patient in the United States.



Laura Joszt, Assistant Managing Editor, AJMC

Latest:

Democrats Push to Address and Restrain Rising Prescription Drug Prices

Prior to the president's final State of the Union address, Democrats announced new plans to investigate drug prices in 2016.


Michaela Fleming

Latest:

Community-Based HIV Care As Effective as Hospital-Based Care for Certain Populations

The findings of the retrospective cohort study were presented in a poster at IDWeek 2019.


Elaine Wong, PharmD

Latest:

How to Treat Common Skin Infections

Helpful advice for your patients on treating bacterial skin infections.



Ellen Huang, PharmD

Latest:

Postoperative Pain Management

Postoperative pain management presents a major challenge to patients and health care providers.


Abdullah Assiri, PharmD

Latest:

Management of Inflammatory Bowel Disease

An Effective Treatment Plan Is Crucial for Patients with Crohn's Disease and Ulcerative Colitis.




Miley G. Nikirk

Latest:

Combating Advancing Cancers With CAR T-Cell Therapy

Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.



Dorothy McCoy, PharmD, BCPS-AQ ID

Latest:

Management of Community-Acquired Pneumonia in Adults

Here is an overview of the key Issues for hospital pharmacists.


Surabhi Dangi-Garimella, PhD, Managing Editor, Evidence-Based Oncology

Latest:

MedPAC Recommends Congress Cut Part B Reimbursement for 340B Entities

A proposal to reduce Medicare Part B payment rates for hospitals participating in the 340B Drug Pricing Program has been approved 14-3 by the Medicare Payment Advisory Commission.